NEW YORK (GenomeWeb) – Next-generation sequencing-based testing firm Courtagen Life Sciences has raised $7.5 million, according to a document filed with the US Securities and Exchange Commission this week. 

The company said there were three investors in the round but did not name them. It did not say how proceeds would be used. A Courtagen spokesman said that the $7.5 million is part of a total financing round of about $17 million expected to be completed in a few weeks. He declined further comment. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.